Format

Send to

Choose Destination
Rheum Dis Clin North Am. 2019 Aug;45(3):359-367. doi: 10.1016/j.rdc.2019.04.008. Epub 2019 May 30.

Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?

Author information

1
Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, 535 East 70th Street, New York, NY 10021, USA. Electronic address: ssrheum@gmail.com.
2
Department of Ophthalmology, Manhattan Eye, Ear, and Throat Hospital, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

Abstract

Hydroxychloroquine and quinacrine are frequently used to treat rheumatic diseases. Ocular toxicity, although infrequent, is one of the potential side effects of antimalarial therapies. Current recommendations are unifocal in being developed by only ophthalmologists who do not treat patients for their rheumatic diseases. The data used to create the recommendations are meager and retrospective. Comanagement of patients with rheumatic disease who are exposed to antimalarial therapies requires a greater interaction between ophthalmologists and rheumatologists.

KEYWORDS:

Antimalarials; Hydroxychloroquine; Ocular toxicity; Quinacrine; Retinopathy

PMID:
31277749
DOI:
10.1016/j.rdc.2019.04.008

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center